DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for partial epilepsy — screening already-approved drugs against its 47-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePartial epilepsy maps to a 47-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for partial epilepsy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
glutamate ionotropic receptor AMPA type subunit 2 (GRIA2) — GRIA2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gludrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3RN8 · 1.7 Å · ligand GLUTAMIC ACID (GLU). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annual Review of Medicine · 1994 · 56 citations
MECHANISM OF EPILEPSY
AbstractEpilepsy is a collection of diverse disorders that together affect approximately 1% of the general population. Current therapies are largely symptomatic and are aimed at controlling seizures in affected individuals. This review focuses on emerging insights into mechanisms underlying the most common form of epilepsy--complex partial epilepsy--and also addresses progress in molecular genetic approaches. Such developments will hopefully lead to more effective therapies.
Newly available treatments for epilepsy: review of clinical studies of lacosamide, ezogabine, perampanel and eslicarbazepine acetate
AbstractDespite that many different treatment options are available for epilepsy, approximately 30% of epilepsy patients still remain refractory. Among patients who are refractory to medical treatment, only small percentage of patients may be candidates for epilepsy surgery. For the remaining majority of refractory seizure patients, combination treatment of different medications, especially with new or novel medications, can be an appropriate therapeutic option. The most recent antiepileptic medications may offer new mechanisms of action and more favorable safety profiles than the previous-generation medications. The purpose of this review article is to review clinical studies of newly approved medications for partial epilepsy such as lacosamide, ezogabine, perampanel and eslicarbazepine acetate.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
